Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2022 | $18.00 | Buy | Jefferies |
| 7/1/2022 | $23.00 | Overweight | Piper Sandler |
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
Over the past 3 months, 4 analysts have published their opinion on VectivBio Holding (NASDAQ:VECT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 3 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 These 4 analysts have an average price target of $19.0 versus the current price of VectivBio Holding at $16.5, implying upside. Below is a summary of how these 4 analysts rated VectivBio Holding over the past 3 months. The greater the number o
Upgrades MoffettNathanson upgraded the previous rating for Zoom Video Communications Inc (NASDAQ:ZM) from Underperform to Market Perform. Zoom Video Comms earned $1.16 in the first quarter, compared to $1.03 in the year-ago quarter. At the moment, the stock has a 52-week-high of $124.05 and a 52-week-low of $60.45. Zoom Video Comms closed at $71.41 at the end of the last trading period. Evercore ISI Group upgraded the previous rating for CCC Intelligent Solutions Holdings Inc (NASDAQ:CCCS) from In-Line to Outperform. For the first quarter, CCC Intelligent Solutions had an EPS of $0.07, compared to year-ago quarter EPS of $0.08. The current stock performance of CCC Intelligent Solutions sh
Piper Sandler analyst Christopher Raymond downgrades VectivBio Holding (NASDAQ:VECT) from Overweight to Neutral and lowers the price target from $25 to $17.
SC 13G/A - VectivBio Holding AG (0001836379) (Subject)
SC 13D - VectivBio Holding AG (0001836379) (Subject)
SC 13G - VectivBio Holding AG (0001836379) (Subject)
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-
- Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, an
BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET. A live webcast will be accessible under ‘Events & Presentations' in the ‘Investors & Media' section of VectivBio's website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio's website approximately two hours after the conference call and will be available for thirty days
Jefferies initiated coverage of VectivBio with a rating of Buy and set a new price target of $18.00
Piper Sandler initiated coverage of VectivBio with a rating of Overweight and set a new price target of $23.00
SVB Leerink initiated coverage of VectivBio Holding with a rating of Outperform and set a new price target of $28.00
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
EFFECT - VectivBio Holding AG (0001836379) (Filer)
EFFECT - VectivBio Holding AG (0001836379) (Filer)
EFFECT - VectivBio Holding AG (0001836379) (Filer)